In Segment C, participants will receive ABBV-744 and oral navitoclax. In Phase D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or even the individuals are not able to tolerate the study drugs. There might be higher treatment stress for contributors Within this trial https://clinical-trial-recruitmen68912.blogproducer.com/38719470/what-does-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-mean